Connect with us

Featured Stocks

Why Lexaria Bioscience Corp (OTCMKTS:LXRP) Is A Comeback Play



Lexaria Bioscience

Lexaria Bioscience Corp (OTCMKTS:LXRP) brightest days lie ahead. The sentiments shared by Chief Executive Officer, Chris Bunka, are slowly coming to fruition, going by recent price action activity. After a steep pullback in 2019, the stock has once again started climbing higher, as investors react to milestones achieved in 2019 that affirm long-term prospects.

Lexaria Bioscience Catalysts and Price Analysis

A confirmation that the global innovator in drug delivery systems achieved almost everything it set out to accomplish in 2019 continues to strengthen market sentiments. The inking of strategic partnerships with Fortune 500 style companies is another development that the management continues to tout.

Likewise, Lexaria Bioscience succeeded in getting its DehydraTECH technology to market, consequently creating an avenue for generating long-term value. The company’s Intellectual Property strategy has also started to pay dividends, affirming what is at stake going forward. Reports that the company is already experiencing an increase in revenues is another catalyst that continues to shore the stock’s sentiments and prospects in the markets.

Lexaria Bioscience has already started bottoming out from all-time lows in what appears to be the development of a positive trend. A 10% plus rally from one-year lows continue to fuel optimism that the stock has clocked a bottom and due for a correction higher.

Standing in the way of the emerging uptrend is the $0.50 mark, which is the immediate short-term resistance level. A rally followed by a close above the critical technical level should pave the way for bulls to push the stock to the $0.70 mark, the next substantial resistance level.

For the stock to turn bullish after the underperformance of the past year, it needs to rise and find support above the $1 a share level. Conversely, failure to take out the critical resistance level would leave the stock susceptible to continued short-selling pressure.

About Lexaria Bioscience

Lexaria Bioscience bills itself as a global innovator of drug delivery platforms. Its flagship product is DehydraTECH technology designed to enhance the way active pharmaceutical ingredients enter the bloodstream. The company also operates a licensed in-house research laboratory that holds a robust intellectual property portfolio with 16 patents.

DehydraTECH Technology Strong demand

After a roller coaster 2019, the tide is slowly moving in favor of Lexaria Bioscience as investors take note of the milestone achieved that affirm long-term prospects. For instance, the company opened discussions with a number of Fortune 500 style companies that continue to ask about its DehydraTECH technology for use in the delivery of cannabis ingredients.

In addition to positioning DehydraTECH for use in the burgeoning cannabis industry, the company is also looking to gain approval for its use in the next-generation nicotine products within America and around the world. The technology has already attracted interest from Altria, a heavyweight in combustible and non-combustible tobacco products.

“Lexaria strongly believes that, given the choice, many of the world’s one billion smokers would elect to experience their nicotine in a manner that does not rely on either smoking or vaping, and Lexaria can help enable these alternatives,” said Chris Bunka, CEO of Lexaria Bioscience and Lexaria Nicotine.

Likewise, the company is looking to build upon a contractual relationship it inked with a GMP certified FDA registered production company. Under the terms of the agreement, the company is looking to get enhanced DehydraTECH powders for marketing in the U.S. The deal should help the company meet the strong demand from many companies looking for DehydraTECH bulk powders for use in specific product lines.

IP Strategy and Revenue Growth Outlook

The company’s IP strategy is already bearing fruits following the securing of patents for the use of DehydraTECH for treatment of various health conditions such as heart disease and Alzheimer in Australia

Lexaria Bioscience has also started to experience an increase in revenue, expected to support sustainable and supportive growth. Given the growing clientele base, management expects revenues to more than double in 2020.

Bottom Line

Lexaria Bioscience shares appear to be undervalued, given the milestones achieved that positions the company for accelerated growth in 2020. With the company projecting double-digit revenue growth at the back of the growing demand of the flagship DehydraTECH technology, the future certainly looks bright.

That said, the stock looks set to continue climbing higher after a steep pullback in 2019, on renewed investor interest, amidst improving fundamentals.

We will be updating our subscribers as soon as we know more. For the latest updates on Lexaria Bioscience, sign up below!

Disclosure: We have no position in Lexaria Bioscience and have not been compensated for this article.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Featured Stocks

Helix TCS Stock (OTCMKTS:HLIX): A Fundamentally Attractive Investment



Helix TCS stock

Helix TCS Stock (OTCMKTS:HLIX) is turning out to be an interesting pick after a steep pullback in 2019. The stock appears to be trading at a big discount going by the solid fundamentals that support a bounce back from current lows. If you are looking for a company seeing plenty of opportunities on the horizon then Helix TCS stock fits the bill.

Helix TCS Stock Catalysts and Price Analysis

The company is currently ranked at number 32 on the Deloitte Technology 500 fastest growing companies. The impressive rating stems from the company reporting impressive financial results depicted by an 80% increase in revenue and a 39% increase in cash flow from operations.

Likewise, the company has moved to strengthen its prospects in the hemp business by launching the nation’s first hemp tracking system. Similarly, the company has inked a strategic partnership with Alt Thirty Six for the launch of digital payments targeting thousands of dispensaries across the U.S

Reports that Helix TCS BioTrack traceability stem processed over $11 million transactions in the first week of recreational sales attest to what could turn out to be a break out year for the company and its technology.

It thus does not come as a surprise that the company’s stock has started to pick up some steam after a roller coaster 2019. A 10% plus rally since the start of the year affirms renewed investor interest in response to the wave of…

Continue Reading

Featured Stocks

Why OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) Is A Promising Stock In 2020



OWC Pharmaceutical Research

In 2020, investors are looking for cannabis stocks that can deliver excellent returns following a disappointing 2019, which saw many pot stocks crash to multiyear lows. OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) stands out as a promising cannabis stock to own in 2020.

About OWC Pharmaceutical Research

The cannabis stock universe is vast, so for investors who may have just come across OWC Pharmaceutical for the first time an introduction of the company is in order.

OWC Pharmaceutical is an Israel-based cannabis research company. It is focused on research and development of cannabis-based medical products. The company’s work currently includes development of cannabis-based treatments for a variety of diseases and disorders such as multiple myeloma, psoriasis and fibromyalgia.

Moreover, OWC Pharmaceutical provides consulting services to both government and private entities in the field of medical cannabis programs.

OWC Pharmaceutical Research exited 2019 on a high note

While 2019 ended up being one of the toughest year for cannabis stocks, OWC Pharmaceutical had strong finish to the year. The stock gained 35% on December 31. Before that, the stock rose 65% on December 30. The back-to-back gains in the final days of 2019 helped OWC Pharmaceutical cut its losses for the year but also signaled improving investor sentiment on the stock heading into the new year.

OWC Pharmaceutical finished 2019 at $0.089, having pulled from a low of $0.0045 at the beginning of December.


Continue Reading

Featured Stocks

Planet 13 Stock (CNSX:PLTH) (OTCMKTS:PLNHF): Is It A Buy Or Sell?



Planet 13 stock

The marijuana stocks universe presents a variety of choices. But not all choices are great. You want to put your money in a marijuana company with a strong competitive advantage, great growth potential, and solid financials. If you are looking for a great pot stock to buy heading into 2020, Planet 13 stock (CNSX:PLTH) (OTCMKTS:PLNHF) is a strong candidate.

About Planet 13 stock

For investors who may be learning about Planet 13 Holdings for the first time, this is a vertically-integrated marijuana business. It is one of the leading marijuana companies in the Nevada market. Planet 13 Holdings is engaged in the cultivation, processing, and retail of marijuana products and it already has several marijuana brands to its credit. It operates the largest marijuana retail outlet in the world.

What you should know about Planet 13 stock

For marijuana sector in general, 2019 has generally been a rough year. Many marijuana stocks have dropped to multiyear lows. As the charts show, Planet 13 Holdings stock has been through a lot of ups and downs this year. Still, those swings have delivered decent returns for investors who know how to play stocks like Planet 13 Holdings in volatile periods.

Presently, Planet 13 Holdings stock is trading at $1.64. The stock began the year at $1.00. It jumped to $1.64 in February, thereby returning nearly 65% in space of a few weeks. There was a…

Continue Reading

MJ Stocks